产品
编 号：F397008
分子式：C21H26ClN3OS
分子量：403.97
分子式：C21H26ClN3OS
分子量：403.97
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
400
In-stock
1g
480
In-stock
5g
1040
In-stock
结构图
CAS No: 58-39-9
产品详情
生物活性：
Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation.
体内研究：
Perphenazine (oral gavage, 180 mg/kg, every other day for 21 days) induces liver injury and lysosomal membrane damage in ICR mice.Perphenazine (oral administration, 10 mg/kg, every other day for 6 days) attenuates morphological phenotype in mouse models of Th2-type allergic dermatitis.Animal Model:ICR mice
Dosage:10, 30, 60, 120, 180 mg/kg
Administration:Oral gavage, every other day for 21 days.
Result:Increased histological injury and aminotransferases compared with control.
Animal Model:Oxazolone-treated animal model of dermatitis
Dosage:10 mg/kg
Administration:Oral administration, every other day for 6 days
Result:Decreased The levels of mice ear swelling.
体外研究：
Perphenazine (40 μM, 48 h) inhibits cell viability, and induces cell apoptosis mediated by CTSD (Cathepsin D) in L02 cells.Perphenazine (30 μM, 24 h) induces intense lysosome vacuolation, impaired lysosomal membrane, and induces lysosomal membrane permeabilization (LMP), ultimately triggering lysosomal cell death in L02 cells.Perphenazine (10-40 μM, 24 h) inhibits autophagic flux in L02 cells.Perphenazine (1 μM, 24 h) decreases glioblastoma U-87 MG cell migration and invasion.
Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation.
体内研究：
Perphenazine (oral gavage, 180 mg/kg, every other day for 21 days) induces liver injury and lysosomal membrane damage in ICR mice.Perphenazine (oral administration, 10 mg/kg, every other day for 6 days) attenuates morphological phenotype in mouse models of Th2-type allergic dermatitis.Animal Model:ICR mice
Dosage:10, 30, 60, 120, 180 mg/kg
Administration:Oral gavage, every other day for 21 days.
Result:Increased histological injury and aminotransferases compared with control.
Animal Model:Oxazolone-treated animal model of dermatitis
Dosage:10 mg/kg
Administration:Oral administration, every other day for 6 days
Result:Decreased The levels of mice ear swelling.
体外研究：
Perphenazine (40 μM, 48 h) inhibits cell viability, and induces cell apoptosis mediated by CTSD (Cathepsin D) in L02 cells.Perphenazine (30 μM, 24 h) induces intense lysosome vacuolation, impaired lysosomal membrane, and induces lysosomal membrane permeabilization (LMP), ultimately triggering lysosomal cell death in L02 cells.Perphenazine (10-40 μM, 24 h) inhibits autophagic flux in L02 cells.Perphenazine (1 μM, 24 h) decreases glioblastoma U-87 MG cell migration and invasion.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备